Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 26 Triple Negative Breast Neoplasms 13 Prostatic Neoplasms 12 Ovarian Neoplasms 12 Neoplasms 10 Neoplasm Metastasis 8 Fallopian Tube Neoplasms 6 Leukemia, Myeloid, Acute 5 Small Cell Lung Carcinoma 4 Pancreatic Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Carcinoma, Renal Cell 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Solid Tumor 1 Sarcoma 1

Interventions

pembrolizumab 92 Gemcitabine 55 Nivolumab 49 Cisplatin 38 atezolizumab 31 Carboplatin 30 avelumab 25 enfortumab vedotin 24 Docetaxel 23 Magnetic Resonance Spectroscopy 18 Ipilimumab 17 Paclitaxel 16 Mitomycin 15 Specimen Handling 14 durvalumab 11 toripalimab 10 sacituzumab govitecan 10 Pemetrexed 10 cabozantinib 9 Taxes 8 vinflunine 7 Cyclophosphamide 7 tislelizumab 6 Injections 6 Bevacizumab 6 pemigatinib 5 fludarabine 5 disitamab vedotin 5 Standard of Care 5 Radiosurgery 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Transitional Cell × talazoparib × Clear all

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡